Floatz logo

Epirubicin

Sarcomatoid Renal Cell Carcinoma

City of Hope Medical CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Sarcomatoid Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
City of Hope Medical Center
Phase 3BB
Ipilimumab
City of Hope Medical Center
Phase 3BB
Bms-907351
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
City of Hope Medical Center
Phase 2CCC
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 2CCC

View all 11 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →